Featured Research

from universities, journals, and other organizations

Promising Treatment For Huntington's Disease Soon To Be Tested Clinically

Date:
May 3, 2006
Source:
Institut Curie
Summary:
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.

A protein that "releases" BDNF BDNF (green) and clathrin (red), a marker of BDNF-containing vesicles, are abundant in the Golgi apparatus of neurons.
Credit: Image copyright S. Humbert-F. Saudou/Institut Curie

At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington’s disease. Like Alzheimer’s and Parkinson’s, Huntington’s disease, is characterized by the abnormal death of neurons.

Related Articles


Cysteamine raises neuronal levels of BDNF protein, a trophic factor which is depleted in Huntington’s disease, and by assaying BDNF in the blood it is possible to evaluate the effect of treatment. If other studies confirm these results, cysteamine could soon be used to treat Huntington’s disease, and BDNF could serve as a biomarker of its efficacy.

Huntington’s disease is a rare (1 in 10 000 people) neurological condition whose onset occurs between the ages of 35 and 50. The most striking symptoms are involuntary abnormal movements of the limbs, head and neck. These are accompanied by mental symptoms (anxiety, irritability, depression) and intellectual deterioration leading to dementia. Death occurs 15 to 20 years after disease onset as a result of complications (pulmonary embolism, pneumonia, other infection).
Clinical diagnosis is often difficult and time-consuming because the symptoms are highly variable and easy to confuse with psychological disorders. It must be confirmed by examination of the brain (by magnetic resonance imaging) or by genetic testing.

A mutant protein: huntingtin

Huntington’s disease is an autosomal dominant inherited disorder: if one of the two parents carries the mutant gene, 50% of the offspring will inherit this mutation and one day develop the disease. The IT15 gene responsible for the disease is located on chromosome 4 and encodes a protein called huntingtin, whose function is unknown. Normal huntingtin contains repeats of glutamine, an amino acid, but when there are more than 35 to 40 glutamines, huntingtin is considered to be mutant and induces the death of neurons, thereby causing the disease. Symptoms appear increasingly early as the number of glutamine repeats increases.

The same type of mutation causes other neurodegenerative diseases, each of which specifically affects different regions of the brain. In Huntington’s disease, there is progressive loss of neurons of the striatum, a region of the brain involved in the control of movement.

Thwarting apoptosis of neurons

At the Institut Curie, Fr้d้ric Saudou and Sandrine Humbert(1) have already shown that brain-derived neurotrophic factor (BDNF)(2), when present in adequate amounts in the striatal neurons, blocks the effect of mutant huntingtin(3). Conversely, when BDNF levels decrease, the disease progresses. In patients with Huntington’s disease, BDNF levels in the striatal neurons are subnormal.

Under the direction of Fr้d้ric Saudou and Sandrine Humbert, Maria Borell-Pag่s has now shown in a mouse model of Huntington’s disease that cysteamine raises BDNF levels in striatal neurons. Cysteamine stimulates the secretion of BDNF, which explains its neuroprotective effect in different murine models of the disease. Cysteamine is already used clinically to treat a rare childhood disease called cystinosis(4).

The present study also demonstrates that BDNF, which can be assayed in blood, can be used as a biomarker. BDNF levels are decreased in animal models of Huntington’s disease, and are raised by cysteamine. Assay of BDNF in the blood should therefore enable evaluation of the efficacy of cysteamine treatment. A national, multicenter clinical trial is scheduled to begin by the end of 2006, and will test the effect of cysteamine and the value of BDNF as a biomarker in about 100 patients.

If these conclusions are confirmed clinically, cysteamine could become a routine treatment for Huntington’s disease.


Story Source:

The above story is based on materials provided by Institut Curie. Note: Materials may be edited for content and length.


Cite This Page:

Institut Curie. "Promising Treatment For Huntington's Disease Soon To Be Tested Clinically." ScienceDaily. ScienceDaily, 3 May 2006. <www.sciencedaily.com/releases/2006/05/060503101319.htm>.
Institut Curie. (2006, May 3). Promising Treatment For Huntington's Disease Soon To Be Tested Clinically. ScienceDaily. Retrieved January 31, 2015 from www.sciencedaily.com/releases/2006/05/060503101319.htm
Institut Curie. "Promising Treatment For Huntington's Disease Soon To Be Tested Clinically." ScienceDaily. www.sciencedaily.com/releases/2006/05/060503101319.htm (accessed January 31, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Saturday, January 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) — The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
Study Shows Newborn Chicks Count From Left to Right Just Like Humans

Study Shows Newborn Chicks Count From Left to Right Just Like Humans

Buzz60 (Jan. 30, 2015) — Researchers for the first time identified human&apos;s innate preference for associating low and high numbers with the left and right respectively in another species. Jen Markham (@jenmarkham) explains. Video provided by Buzz60
Powered by NewsLook.com
Best Mood Elevating, Feel Good Shakes & Smoothies

Best Mood Elevating, Feel Good Shakes & Smoothies

Buzz60 (Jan. 30, 2015) — You can elevate your mood by having a meal in a glass. Fitness and nutrition expert John Basedow (@JohnBasedow) offers the best &apos;feel good&apos; smoothies and shakes chock full of depression-relieving ingredients...including apples, berries, lemons, cucumbers, papaya, kiwi, spinach, kale, whey protein, matcha, ginger, turmeric and cinnamon. Video provided by Buzz60
Powered by NewsLook.com
Poll Says Firstborn Is Responsible, Youngest Is Funnier

Poll Says Firstborn Is Responsible, Youngest Is Funnier

Newsy (Jan. 30, 2015) — According to a poll out of the U.K., eldest siblings feel more responsible and successful than their younger siblings. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins